The evolving BTK story in multiple sclerosis: Clinical Report

Among notable clinical readouts this week was a Phase III miss by Sanofi that further cements Roche’s dominance in multiple sclerosis.

After producing a statistically significant slowing of progression in a Phase III study in secondary progressive MS, Sanofi (Euronext:SAN; NASDAQ:SNY) announced that its BTK inhibitor, tolebrutinib, failed to replicate the effect in patients with primary progressive disease, in which symptoms worsen from the outset without a relapsing phase...